1. Home
  2. MGRX vs PMCB Comparison

MGRX vs PMCB Comparison

Compare MGRX & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mangoceuticals Inc.

MGRX

Mangoceuticals Inc.

HOLD

Current Price

$0.36

Market Cap

7.1M

Sector

Technology

ML Signal

HOLD

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.70

Market Cap

8.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGRX
PMCB
Founded
2021
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
8.2M
IPO Year
2023
2001

Fundamental Metrics

Financial Performance
Metric
MGRX
PMCB
Price
$0.36
$0.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
463.9K
317.7K
Earning Date
05-14-2026
03-17-2026
Dividend Yield
N/A
N/A
EPS Growth
55.17
277.22
EPS
N/A
N/A
Revenue
$456,021.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.63
52 Week High
$2.75
$1.51

Technical Indicators

Market Signals
Indicator
MGRX
PMCB
Relative Strength Index (RSI) 46.02 44.87
Support Level $0.32 $0.66
Resistance Level $0.49 $0.78
Average True Range (ATR) 0.05 0.05
MACD -0.01 -0.01
Stochastic Oscillator 13.75 22.19

Price Performance

Historical Comparison
MGRX
PMCB

About MGRX Mangoceuticals Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: